Online inquiry

IVTScrip™ mRNA-Human ALDH5A1, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK16003MR)

This product GTTS-WK16003MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ALDH5A1 protein. This product can be used in Oogenesis phase fetal germ cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Human
RefSeq NM_001080.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 7915
UniProt ID P51649
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ALDH5A1, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WK16003MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK19991MR IVTScrip™ mRNA-Human ANKK1, (Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ANKK1
GTTS-WK15714MR IVTScrip™ mRNA-Human ALG14, (Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ALG14
GTTS-WK21383MR IVTScrip™ mRNA-Human AKTIP, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AKTIP
GTTS-WK25255MR IVTScrip™ mRNA-Human ARAF, (Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ARAF
GTTS-WK21409MR IVTScrip™ mRNA-Human ALDOB, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ALDOB
GTTS-WK11250MR IVTScrip™ mRNA-Human ACSM1, (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACSM1
GTTS-WK15415MR IVTScrip™ mRNA-Human ALG2, (Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ALG2
GTTS-WK2830MR IVTScrip™ mRNA-Human Carboxypeptidase M, (Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Carboxypeptidase M
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW